Trials of IV SNX-111 Paused, but Phase III Pain Trials Continue
MENLO PARK, Calif-Neurex Corporation has announced a pause in enrollment of a trial of intravenous SNX-111 for patients with severe head trauma, to review data from earlier studies for overall risk/benefit. The agent is an N-type neuron-specific calcium blocker derived from the venom of the cone snail.
MENLO PARK, CalifNeurex Corporation has announced a pause in enrollment of a trial of intravenous SNX-111 for patients with severe head trauma, to review data from earlier studies for overall risk/benefit. The agent is an N-type neuron-specific calcium blocker derived from the venom of the cone snail.
SNX-111 is also being investigated in an independent program for the treatment of malignant and neuropathic chronic pain syndromes, with two phase III analgesia trials underway. In these studies, SNX-111 is given intrathecally at doses 10,000 times lower than those used in head trauma. Therefore, the company believes that these pain trials will not be affected by the results of the analysis of the head trauma data.
Elevating the Quality of Cancer Care via Cross-Department Collaboration
Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.
